Sign In
Buy ABEO
$5.67
-0.0200 (-0.351%)
At Close: Jun 03, 2026
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:30am, Monday, 01'st Jun 2026
CLEVELAND, June 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awar
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
08:30am, Tuesday, 26'th May 2026
CLEVELAND, May 26, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in June 2026:
Abeona Therapeutics Inc. (ABEO) Q1 2026 Earnings Call Transcript
03:50pm, Wednesday, 13'th May 2026
Abeona Therapeutics Inc. (ABEO) Q1 2026 Earnings Call Transcript
Abeona Therapeutics Q1 Earnings Call Highlights
10:08am, Wednesday, 13'th May 2026
Abeona Therapeutics NASDAQ: ABEO reported early commercial momentum for ZEVASKYN in the first quarter of 2026, with executives highlighting new patient treatments, expanded treatment-center activation
Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network
09:31am, Wednesday, 13'th May 2026
Abeona Therapeutics Inc. (NASDAQ:ABEO) reported first-quarter earnings Wednesday before the market opened. Here's a rundown of the report.
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
07:30am, Wednesday, 13'th May 2026
- Three patients treated with ZEVASKYN ® in Q1 2026 - - QTC network expands to six sites, with two new additions on the East Coast - - In-licensed radically novel engineered T-cell technology with
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02:30pm, Monday, 11'th May 2026
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CLEVELAND, May 01, 2026 (GLOBE NEWSWIRE) -- Abeona Thera
CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need
Abeona Therapeutics® Announces Date of First Quarter Financial Results
08:30am, Monday, 04'th May 2026
CLEVELAND, May 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, May 13, 2026 at 8:30 a.m. ET to discuss its financial r
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:30am, Friday, 01'st May 2026
CLEVELAND, May 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity award
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
08:30am, Tuesday, 07'th Apr 2026
CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effectiv
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:30am, Monday, 06'th Apr 2026
CLEVELAND, April 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awa
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
08:30am, Thursday, 02'nd Apr 2026
CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of NewYork-Presbyterian/Columbia University Irving Medical Center in New York, NY as th
LENZ Therapeutics (NASDAQ:LENZ) versus Abeona Therapeutics (NASDAQ:ABEO) Critical Comparison
01:10am, Wednesday, 25'th Mar 2026
Abeona Therapeutics (NASDAQ: ABEO - Get Free Report) and LENZ Therapeutics (NASDAQ: LENZ - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the
Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB
01:18pm, Thursday, 19'th Mar 2026
Abeona Therapeutics maintains a "Buy" rating, driven by ZEVASKYN's commercial launch for RDEB and strong early demand signals. ZEVASKYN is the first autologous cell sheet-based gene therapy for RDEB,
